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Curcumin: A multi-target disease-
modifying agent for late-stage 
transthyretin amyloidosis
Nelson Ferreira1,2, Nádia P. Gonçalves1,2,3, Maria J. Saraiva1,2,3 & Maria R. Almeida1,2,3
Transthyretin amyloidoses encompass a variety of acquired and hereditary diseases triggered by 
systemic extracellular accumulation of toxic transthyretin aggregates and fibrils, particularly in 
the peripheral nervous system. Since transthyretin amyloidoses are typically complex progressive 
disorders, therapeutic approaches aiming multiple molecular targets simultaneously, might 
improve therapy efficacy and treatment outcome. In this study, we evaluate the protective effect 
of physiologically achievable doses of curcumin on the cytotoxicity induced by transthyretin 
oligomers in vitro by showing reduction of caspase-3 activity and the levels of endoplasmic reticulum-
resident chaperone binding immunoglobulin protein. When given to an aged Familial Amyloidotic 
Polyneuropathy mouse model, curcumin not only reduced transthyretin aggregates deposition 
and toxicity in both gastrointestinal tract and dorsal root ganglia but also remodeled congophilic 
amyloid material in tissues. In addition, curcumin enhanced internalization, intracellular transport 
and degradation of transthyretin oligomers by primary macrophages from aged Familial Amyloidotic 
Polyneuropathy transgenic mice, suggesting an impaired activation of naïve phagocytic cells exposed 
to transthyretin toxic intermediate species. Overall, our results clearly support curcumin or optimized 
derivatives as promising multi-target disease-modifying agent for late-stage transthyretin amyloidosis.
The accumulation of misfolded proteins as insoluble amyloid fibrils is a key pathognomonic feature of many 
neurodegenerative diseases, including Familial Amyloidotic Polyneuropathy (FAP), type II diabetes, Alzheimer’s, 
Parkinson’s and Huntington’s diseases. In most of these pathologies, the end stage aggregated species that accu-
mulate in tissues are composed mostly by 6–10 nm twisted β -pleated-fibrils, in which the polypeptide chain is 
arranged in sheets perpendicular to the fibril axis being hydrogen bonding parallel1. Although amyloid fibrils 
have been reported to be toxic2, accumulating evidence suggests that the non-fibrillar oligomer intermediaries are 
the primary culprits for neurodegeneration and exert their toxicity through distinct mechanisms3.
Transthyretin (TTR) is an abundant plasma protein that is mainly synthesized by the liver and choroid 
plexuses of the brain. TTR in its homotetrameric structure acts as a carrier protein for thyroid hormones and 
retinol-binding protein in plasma and cerebrospinal fluid4. Extracellular TTR aggregation and deposition triggers 
inflammation and oxidative damage5, disruption of calcium homeostasis6, extracellular matrix remodeling7, acti-
vation of heat shock response and endoplasmic reticulum (ER) stress pathways6,8, including common molecular 
actors and scenarios, that resemble in many features those associated to local amyloidoses affecting the central 
nervous system such as Alzheimer’s and Parkinson’s diseases.
FAP is a fatal neurodegenerative disorder characterized by the extracellular deposition of aggregates and fibrils 
of mutant forms of TTR, particularly in peripheral nerves and ganglia of the peripheral nervous system. Although 
the most common TTR mutation leading to FAP gives origin to a substitution of methionine for valine at position 
30 (TTR V30M), more than one hundred amyloidogenic TTR variants have been described. Different mutations 
in the TTR gene are associated with distinct age of onset, disease penetrance, clinical phenotype, prognosis and 
clinical outcome9. In addition to familial TTR- associated forms of amyloid, senile systemic amyloidosis (SSA) is 
a nonhereditary, late onset sporadic form of TTR amyloidosis that is typically related with wild-type TTR amyloid 
deposition in the heart, leading to cardiac dysfunction and ultimately death10.
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Through a combination of compound library screens and epidemiological data, many low molecular weight 
organic compounds have been suggested as effective therapeutic and prophylactic agents against amyloidosis. 
The most striking aspect that has emerged from recent studies is that some of these small molecules, in particular 
natural occurring polyphenols, do not act on a single target in the multi-step amyloidogenic cascade; rather, they 
seem to inhibit/redirect different steps of the amyloid molecular dynamics and also modulate the biology of cells 
and tissues where amyloid deposition takes place11,12. Among those polyphenols, curcumin, a natural occurring 
diarylheptanoid isolated from Curcuma longa, has been found to modulate oligomerization and fibril formation 
of several amyloid proteins, including TTR12,13, α -synuclein14 and amyloid-β 15.
Curcumin has anti-oxidant and anti-inflammatory properties that have also been suggested to play a protec-
tive role in a variety of chronic pathologies such as cancer, atherosclerosis, and neurodegenerative diseases16. In 
addition, curcumin can efficiently chelate amyloid associated metal ions, such as Fe2+, Zn2+ and Cu2+ which may 
reduce amyloid aggregation or oxidative neurotoxicity in vivo17. Furthermore, curcumin is widely used as thera-
peutic agent in Chinese and Indian Ayurvedic medicine and is “generally recognized as safe” by the U.S. Food and 
Drug Administration. Epidemiological studies conducted in India, where curcumin is highly consumed, showed 
that Alzheimer’s disease incidence is significantly lower than that reported from the western world18.
These observations together with the findings that curcumin disaggregates TTR amyloid fibrils in vitro11 and 
activates innate immune system promoting amyloid clearance19, prompted us to investigate the effect of curcumin 
supplementation in a late-stage mouse model for FAP.
Results
Curcumin reduces ER stress and protects Schwann cells from entering into the apoptotic 
signaling pathway upon exposure to TTR aggregates. We investigated the impact of curcumin on 
TTR aggregate-induced ER stress response and apoptosis by exposing RN22 cells to TTR oligomers formed in 
the absence or presence of different curcumin concentrations. As expected from previous work6, TTR oligomers, 
but not soluble TTR, triggered a remarkable increase in the intracellular amount of BiP, the central regulator for 
the ER-stress response20, indicating cellular toxicity (Fig. 1). In strong contrast, we observed no such effect when 
identical amounts of oligomers formed in the presence of curcumin were added to the RN22 cells, indicating 
that these species are less toxic than untreated oligomeric intermediaries (Fig. 1). Moreover, exposure of cells to 
Figure 1. Curcumin inhibits TTR oligomers-dependent activation of ER-chaperone BiP. (A) Anti-BiP 
Western blot of protein extracts from Schwannoma cells exposed to soluble TTR Y78F (TTR) or to TTR 
Y78F oligomers (Oligomers) or TTR Y78F oligomers pre-treated with curcumin for 24 h (final concentration 
of protein in cell culture medium 2 μ M and curcumin 0.001–11 μ M). In parallel, cells were incubated with 
curcumin alone, at highest concentration used (Curc. 11 μ M). (B) Bar graph represents quantification of data 
and is presented as mean ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001).
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curcumin alone (up to 11 μ M) did not interfere with BiP expression along the range of concentrations used in 
the assay.
In addition, toxicity of TTR aggregate intermediaries was also studied through a standardized caspase-3 assay 
in this Schwann cell line. Unlike soluble TTR, TTR oligomeric species induced substantial caspase-3 activity 
in RN22 cells, indicative of cell damage and entry into the apoptotic signaling pathway. On the other hand, cell 
exposure to oligomers formed in the presence of curcumin resulted in a significant dose-dependent reduction of 
caspase-3 activity (Fig. 2). Moreover, no significant alteration in this enzyme activity was noted when cells were 
incubated with curcumin alone (11 μ M) (Fig. 2).
Evaluation of curcumin effect in a late-stage FAP mouse model. In view of the promising data 
described above and available in the literature concerning in vitro and in vivo studies12,13,21, we investigated the effect 
of dietary supplementation of curcumin on TTR amyloid formation using a late-stage FAP mouse model express-
ing the amyloidogenic human TTR V30M variant on a Hsf-1 heterozygous background (hTTR V30M/Hsf)8. 
The impairment of Hsf-1 expression leads to an extensive and early deposition of non-fibrillar TTR in several 
tissues, including the gastrointestinal tract and the peripheral nervous system. Non-fibrillar TTR species start to 
deposit between 3–6 months of age and gradually evolve to congophilic material, typically after 12 months of age. 
Therefore, this mouse model is highly relevant for testing new therapeutic strategies targeting different stages of 
the pathology.
In the current study, we aimed at evaluating the effect of curcumin in a late-stage disease in which deposition 
of non-fibrillar TTR coexists with birefringent congophilic material in tissues. Protocol design, drug dosage and 
selection of endpoints were based on information from a previous study13. As expected, curcumin supplementa-
tion was very well-tolerated in aged mice and did not produce any observable adverse side effects. No alteration 
was observed in body weight or mortality between animals treated with curcumin and age-matched controls. In 
addition, no histological abnormalities were observed in liver sections stained with hematoxylin and eosin for 
morphologic assessment (data not shown).
Curcumin binds to plasma TTR at the thyroxine binding sites and increases its resistance to 
dissociation. To confirm curcumin binding to TTR in vivo, plasma from mice fed with curcumin-enriched 
diet or standard diet (control) was incubated with radiolabeled thyroxine (T4) ([125I]-T4) and subjected to gel elec-
trophoresis under native conditions. T4-binding proteins were visualized by phosphor imaging analysis, as shown 
in Supp. Fig. 1. The results showed that samples from curcumin treated mice presented considerably less intense 
TTR bands, indicating that after gut absorption and systemic distribution, curcumin selectively competes with T4 
for its binding to TTR (41.74% competition) (Supp. Fig. 1). Densitometry analysis of the IEF gels demonstrated 
Figure 2. Curcumin reduces caspase-3 activity associated with extracellular TTR oligomers. Activity of 
caspase-3 was measured in Schwannoma cells exposed to soluble TTR Y78F (TTR) or to TTR Y78F oligomers 
(Oligomers) or TTR Y78F oligomers pre-treated with curcumin for 24 h (same conditions as indicated in Fig. 1) 
(**p < 0.01; ***p < 0.001; N.S. = non-significant).
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that curcumin chronic supplementation significantly increases TTR resistance to dissociation when compared 
with plasma TTR from untreated animals under the tested conditions (Supp. Fig. 2).
Curcumin decreases TTR deposition and rescues tissue toxicity. TTR levels in plasma were quan-
tified by radial immunodiffusion and showed no statistical difference between mice fed with curcumin-enriched 
diet and control mice (556.8 ± 5.1 μ g TTR/ml and 556.2 ± 5.5 μ g TTR/ml, respectively), indicating that curcumin 
administration did not affect TTR liver synthesis and turnover in vivo.
The effect of curcumin supplementation on TTR deposition and tissue damage was analyzed by SQ-IHC 
and western blotting in different target organs. At the end of treatment, mice were 15.5 months of age thus, as 
expected, control animals showed widespread TTR deposition throughout the interstitial connective tissue of 
DRG, surrounding the perikaryon and in close contact with satellite glial cells8. In strong contrast, sub-chronic 
administration of curcumin inhibited TTR deposition in ganglia associated with spinal nerves, as denoted in 
Figs 3 and 4. Similar results were found in stomach (Figs 5 and 6).
Since extracellular accumulation of TTR aggregates closely correlates with cellular damage and toxicity5,22, we 
next investigated the effect of curcumin treatment on several molecular markers associated with the disease in 
the peripheral nervous system and gastrointestinal tract. In both DRG (Figs 3 and 4) and stomach (Figs 5 and 6), 
we found reduced levels of ER-chaperone BiP. In addition, reduced levels of Fas death receptor were observed in 
curcumin treated mice compared to controls (Fig. 3).
Supporting these observations, several key pro-inflammatory mediators associated with disease pathogenesis, 
namely NF-κ B, IL-1β and TNF-α 8, were found reduced in DRG of curcumin treated mice (Fig. 3). Overall, these 
results sustained that curcumin modulates TTR deposition in both gastrointestinal tract and peripheral nervous 
system.
Curcumin remodels amyloid deposits and enhances its clearance. Previous data has shown that 
curcumin disaggregates TTR fibrils in vitro12. This prompted us to investigate the effect of curcumin in amyloid 
deposition and extracellular matrix remodeling. The presence of amyloid was detected by Congo red staining in 
stomach, the primary amyloid target-organ in this particular mouse model.
The results showed that 7 out of 14 (50%) control animals exhibited Congo Red-positive material, whereas 
only 1 out of 12 (8%) curcumin treated animals presented congophilic amyloid deposits (Fig. 5). These results 
were corroborated by the reduced levels of MMP-9 (biomarker associated with amyloid extracellular deposi-
tion) in stomach (Fig. 5), thus clearly indicating that curcumin remodels TTR amyloid deposits and extracellular 
matrix in vivo.
Curcumin increases internalization and intracellular transport of  TTR aggregates in macrophages. 
Curcuminoids are known to improve the function of the innate immune system by increasing clearance of aggre-
gates in several amyloid diseases23,24. Therefore, we further investigated the effect of curcumin in bone marrow 
derived macrophages exposed to TTR aggregates. Macrophage culture purity was confirmed for all time points 
analyzed, by staining with F4/80, a well-characterized and extensively referenced mature macrophage marker25,26. 
In control macrophages (treated with vehicle) uptake of extracellular TTR aggregates was scarce (Fig. 7). In 
addition, intracellular transport of TTR aggregates progressed very slowly as shown by limited co-localization 
between those and EEA1 (t = 2 h, Fig. 7) or LAMP-1 (t = 24 h, Fig. 7).
Treated macrophages were exposed to curcumin before addition of TTR aggregates to the cell culture 
medium. Using confocal microscopy, we found that curcumin stimulation resulted in rapid internalization of 
TTR aggregates and lysosomal degradation as shown by co-localization with EEA1 (t = 2 h, Fig. 7) and LAMP-1 
(t = 24 h, Fig. 7), respectively.
The optimal dose of curcumin (1 μ M) was determined using a wide range of concentrations (0.01–100 μ M). 
Concentrations higher than 1 μ M did not increase aggregates internalization by macrophages.
Discussion
The working hypothesis for the TTR amyloid cascade, supported by extensive work and literature, led to the 
notion that stabilizing TTR native structure could be a promising therapeutic approach to stop the production 
of toxic TTR amyloidogenic species. Since FAP and other TTR-related amyloidoses are progressive and complex 
multi-system disorders, therapeutic strategies aiming multiple molecular targets simultaneously, either through 
combination therapies or multi-target-directed compounds, could improve therapy efficacy and treatment 
outcome.
Curcumin has a symmetric and extended conjugated molecular structure that resembles the structure of 
Congo red, the classic gold standard for detecting amyloid deposits21. In addition, curcumin is able to efficiently 
cross the blood-brain barrier, which is an essential feature for therapies aiming amyloid deposition in central 
nervous system27,28. Concerning TTR amyloidosis, previous work from our group has shown that, in vitro, cur-
cumin binding to the largely unoccupied thyroxin binding pockets in the native TTR structure increases its 
resistance to dissociation in non-native monomers that polymerize into toxic aggregates12. Very recently, the 
crystal structure of the complex formed between TTR and curcumin has been determined and it corroborates 
our initial findings by showing that intact curcumin binds at the two T4 binding sites located in the TTR tetramer 
central channel29.
In the present study, we investigated the effect of curcumin supplementation in a late-stage mouse model 
for FAP. After gut absorption and systemic distribution, curcumin selectively interacted with TTR in plasma, 
in the largely unoccupied T4 binding pockets, increasing TTR stability. In addition, curcumin administration 
significantly lowered TTR non-fibrillar deposition and toxicity in tissues, in particular along the gastrointestinal 
tract and DRG. These results confirm the previous study in early stage FAP mice13 and are in accordance with the 
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Figure 3. Curcumin decreases TTR deposition and associated toxicity in DRG of aged hTTR V30M/
Hsf mice. Representative images of immunohistochemistry analysis of TTR, BiP, Fas death receptor, cleaved 
caspase-3, NF-κ B, IL-1β and TNF-α in DRG of mice treated with curcumin (right panels; n = 12) and age-
matched controls (left panels; n = 14); 40× magnification. Bar graphs: quantification of immunohistochemistry 
images is represented as percentage of area occupied ± SEM (***p < 0.001). These observations were supported 
by Western blot analysis of TTR levels after normalization to GAPDH signal intensities (Fig. 4).
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Figure 4. (A) Representative anti-BiP and anti-TTR Western blots of DRG from curcumin- treated (n = 6) 
and control mice (n = 6). (B) Bar graphs illustrate normalized BiP/GAPDH and TTR/GAPDH density 
quantifications ± SEM (***p < 0.001). Similar results were found throughout the GI tract, in particular in 
stomach (Figs 5 and 6).
Figure 5. Curcumin decreases TTR aggregates deposition and associated toxicity in the stomach of aged 
hTTR V30M/Hsf mice. Representative images of immunohistochemistry analysis of TTR, BiP, MMP-9 and also 
Congo red staining of stomach sections of mice treated with curcumin (right panels; n = 12) and age-matched 
controls (left panels; n = 14); 20× magnification. Bar graphs: quantification of immunohistochemistry images is 
represented as percentage of area occupied ± SEM (***p < 0.001).
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working hypothesis for TTR amyloidosis by which stabilizing TTR native fold by small molecules would block 
protein aggregation and toxicity30.
Moreover, after Congo red birefringence analysis of stomach sections, we found that curcumin treated mice 
presented fewer and noticeably smaller congophilic deposits as compared to control mice. These results were 
supported by a substantial reduction on the levels of MMP-9 in treated mice and clearly indicate that curcumin 
promotes amyloid remodeling, reabsorption and extracellular matrix recovery. Our observations corroborate 
the results obtained for other amyloidoses since, for instance, administration of dietary curcumin to aged mouse 
models of AD resulted in labeling Aβ plaques and reducing amyloid levels and plaque burden28,31.
Though our data indicates that curcumin modulates the TTR cascade by direct interaction with TTR aggre-
gate intermediates, we speculate whether the diverse array of molecular targets for curcumin might potentiate 
its neuroprotective effect and improve treatment outcome in vivo. For instance, since high concentrations of 
Zn2+ and Cu2+ can trigger TTR amyloid formation32, it seems reasonable to speculate whether curcumin known 
ability to form complexes with these ions17 might contribute to inhibit abnormal TTR aggregation and toxicity 
in vivo. Moreover, compelling evidence indicates that curcumin is able to suppress inflammation through mul-
tiple signaling pathways33,34. Thus, reduction of the pro-inflammatory response to TTR deposition in DRG, 
observed in curcumin treated mice, might be attributed not only to curcumin anti-amyloidogenic effects but 
also to its well-known capacity to block the production of key mediators of inflammation such as NF-kB, TNF-α, 
or IL-1β 33. However, curcumin has been recognized mainly as an anti-oxidant compound35–37. In accordance, 
a recent study by Moustapha et al.38 revealed that this is the predominant effect at very low doses of curcumin 
(lower than 1 μ M) while at higher concentrations, 10 μ M, it starts inducing early events of autophagy and at even 
higher dosages (> 25 μ M) it induces apoptosis and endoplasmic reticulum stress causing calcium release, with 
destabilization of the mitochondrial compartment and promoting tumor cell death38,39. This hormetic charac-
teristic of curcumin has been detailed using a tumor cell line namely, hepatocellular carcinoma Huh-7 cells38. 
Nonetheless, molecular effects of curcumin on complex cell systems might most likely be cell-type specific in a 
concentration and time-dependent manner.
Defects in the autophagic machinery or mitochondrial dynamics might play a pathological role in neurode-
generative disorders40 and might also be impaired in FAP. In fact, it was recently described that curcumin is able 
to decrease monomeric TTR, by promoting LC3 cleavage, thus enhancing autophagy, in a cell culture system41. 
Importantly, studies of Hsf-1 knock-out mice suggest that Hsf-1 might play a role in the regulation of autophagy 
activity42. Therefore, future studies disclosing the role of autophagy in FAP should also encompass the use of other 
animal models.
Transthyretin, either wild-type or mutant, can be internalized by diverse types of cells, including hepatocytes, 
mouse embryonic fibroblasts, yolk sac cells, sensory neurons and glial cells43–46. Recent work from Misumi and 
colleagues has shown that fibroblasts endocyte and degrade TTR aggregates in vitro and in vivo47. All together 
these studies provide evidence for the complex cellular dynamics underlying TTR catabolism and clearance and 
its impact in the FAP pathology. We speculate that cellular impairment of one or more of these mechanisms might 
shift the amyloid formation/degradation equilibrium towards pathogenic TTR aggregate accumulation in the 
extracellular matrix. Moreover, TTR aggregates internalization might also be deleterious to cells leading to death 
and organ dysfunction, a topic that will need further investigation.
During the last years, considerable focus has been given to the role of the immune system on amyloid pathol-
ogies. Macrophages and microglia are the innate immune cells responsible for clearance of pathogens and waste 
products. Curcuminoids have been reported to enhance phagocytosis of Aβ by upregulating the transcription of 
1,4-mannosyl-glycoprotein 4-β -N- acetyl glucosaminyl transferase and other genes, including Toll-like recep-
tors, typically down-regulated in mononuclear cells of AD patients19. Similarly, we found that pre-exposition of 
Figure 6. (A) Representative anti-BiP and anti-TTR Western blots of stomachs from curcumin-treated 
(n = 6) and control mice (n = 6). (B) Bar graphs: normalized BiP/GAPDH and TTR/GAPDH density 
quantifications ± SEM (***p < 0.001).
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macrophages isolated from aged hTTR V30M/Hsf mice, to physiologically achievable doses of curcumin (1–10 μ M), 
improved their phagocytic uptake and degradation of extracellular TTR amyloid aggregates compared to con-
trol macrophages (exposed to vehicle). Thus, our observations indicate that aged FAP macrophages present 
deficient phagocytic ability, suggesting a possible impairment in their functions. In fact, it has been previously 
Figure 7. Curcumin treated macrophages from FAP mice (hTTR V30M/Hsf mice) present increased 
internalization and degradation of TTR aggregates. Representative pictures of double immunofluorescence 
labeling for TTR (green) and EEA1 (red), TTR (green) and F4/80 (red) or TTR (green) and Lamp-1 (red), 
denoting TTR intracellular aggregates co- localizing with endosomes and lysosomes in curcumin treated 
mice (arrows). Superposition of the labels, with DAPI (blue), is shown. 63× magnification. Data presented is 
representative of three independent experiments. Treated macrophages were pre-exposed to curcumin before 
addition of TTR aggregates to cell culture medium and, by double immunofluorescence confocal microscopy, 
we found that pre- exposition of macrophages with curcumin resulted in rapid internalization of TTR 
extracellular aggregates and lysosomal degradation as shown by co-localization of TTR oligomers and EEA1 
(t = 2 h, Fig. 7) or LAMP-1 (t = 24 h, Fig. 7), respectively.
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demonstrated that nerve biopsies from FAP patients did not display innate cellular infiltrate surrounding amyloid 
deposits, as should be expected5 and that macrophage density is downregulated in a FAP mouse model after an 
injured stimulus26.
Despite the molecular mechanisms underlying the clearance impairment of macrophage are mostly unknown, 
the current study shows that chronic administration of curcumin may modulate the innate immune system 
response to extracellular accumulation of TTR and provide a previously uncharacterized approach for FAP ther-
apy. Future studies will further address the role of macrophages in FAP pathology using different FAP mouse lines 
at different stages of TTR amyloid formation.
Currently, a diverse array of emerging disease-modifying agents is under analysis in human clinical trials38. 
From TTR stabilizers (diflunisal, tafamidis), gene therapies to suppress TTR expression (siRNAs) and amyloid 
fibrils disruptors (doxycycline/TUDCA), the perspectives for an effective therapy for TTR amyloidosis seem 
more encouraging nowadays than ever before. Nevertheless, much is still unknown regarding long-term safety 
and efficacy of such approaches and, with the exception of doxycycline/TUDCA therapy, most of them target only 
early stages of the disease.
Our results suggest curcumin as an interesting compound for late-stage TTR amyloidosis. Taking into account 
its pluripotency, high tolerability, long history of use, and inexpensive cost, we speculate that its combined admin-
istration with available therapies might boost treatment efficacy and outcome for advanced amyloidosis.
In conclusion, the present work demonstrates that curcumin inhibits TTR aggregation in a dose dependent 
manner and enhance TTR aggregates clearance by macrophages in vitro. When administrated to aged FAP mice, 
curcumin not only reduced TTR burden and toxicity but also remodeled congophilic material in tissues. Overall, 
our results clearly support curcumin or optimized derivatives as promising multi-target disease-modifying agent 
for late-stage amyloidosis.
Materials and Methods
Curcumin. Curcumin was purchased from Sigma-Aldrich, St. Louis, MO, USA. Curcumin had ≥ 80% purity 
(HPLC), with total curcuminoids ≥ 94% (HPLC).
Production of recombinant TTR variants. Recombinant TTR V30M and TTR Y78F production, isola-
tion and purification were performed as previously described48.
Preparation of fluorescent TTR oligomers. Soluble TTR V30M in PBS was filtered through 0.2 μ m 
Anotop syringe filters (Whatman, England) and labeled with the fluorescent dye Alexa Fluor 488 (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer’s instructions. TTR aggregates were generated by incubating 
the protein (2 mg/ml), with stirring, at room temperature for 7 days6. Preparations were analyzed by dynamic 
light scattering (DLS) at 25 °C in a Malvern Zetasizer Nano ZS (Malvern, Worcestershire, UK) as previously 
reported, to confirm TTR pathogenic aggregation11.
Cell culture assays to assess ER stress and apoptosis. Soluble TTR was dissolved at 2 mg/ml in PBS 
and curcumin stocks were prepared in dimethyl sulfoxide (DMSO). Soluble TTR was mixed with different con-
centrations of curcumin (0.02–200 μ M) or solvent alone (DMSO). A sample containing only curcumin 200 μ M 
was also prepared. All samples were kept in Eppendorf amber tubes (for light protection) and incubated for 6 days 
at 37 °C to allow aggregation. These samples were then diluted (18× ) in cell culture medium to attain a concen-
tration of 2 μ M TTR and increasing concentrations of curcumin ranging 0.001–11 μ M. Following, these samples 
were added to the cells as following described.
Rat Schwannoma cells (RN22) (American type Cell Collection) were propagated and maintained as described 
previously11. Briefly, 80% confluent cells in Dulbecco’s minimal essential medium (DMEM) supplemented 
with 1% fetal bovine serum were exposed, for 24 h, with: i) vehicle (DMSO); ii) 2 μ M of freshly prepared sol-
uble TTR; and the diluted samples prepared above, namely iii) TTR Y78F oligomers or iv) curcumin-induced 
TTR oligomers or v) 11 μ M of curcumin alone. After treatment, cells were trypsinized and lysed using ice-cold 
lysis buffer containing 5 mM ethylenediamine tetraacetic acid, 2 mM ethylene glycol tetra acetic acid, 20 mM 
3-(N-morpholino) propane sulfonic acid, 1% Triton X-100, 1 mM phenyl methane sulfonyl fluoride (PMSF) 
and a protease inhibitor mix (GE Healthcare). Cell lysates were used for determination of BiP intracellular lev-
els and caspase-3 activity. Protein concentration in lysates was determined using a Bio-Rad protein assay kit. 
Caspase-3 activity was accessed using the CaspACE fluorimetric 96-well plate assay system (Sigma- Aldrich, 
St. Louis, MO, USA) according to the manufacturer’s instructions. For determination of BiP levels by western 
blot analysis equal amounts of protein from lysates were separated in 15% SDS-PAGE and transferred onto a 
nitrocellulose Hybond-C membrane (Amersham Biosciences) using a semi-dry system. The primary antibodies 
and the respective dilutions used were: rabbit polyclonal anti-BiP (1:1000) and mouse monoclonal anti-GAPDH 
(1:3000) (Abcam, Cambridge, UK). Detection was performed with LuminataTM Crescendo (enhanced chemilu-
minescence, Millipore, Billerica, MA). Quantification of blots was performed with a Bio-Rad ChemiDoc XRS 
system using the IMAGELAB software and immunosignals were normalized with GAPDH expression. Results 
are presented as normalized density ± Standard Error of the Mean (SEM).
Ethics statement. All the experiments described herein were approved by the Portuguese General 
Veterinarian Board (authorization number 024976 from DGV-Portugal) and are in compliance with national 
rules and the European Communities Council Directive (2010/63/EU), for the care and handling of laboratory 
animals.
FAP transgenic mouse model. Aged transgenic mice for human TTR V30M in a TTR null background, 
heterozygous for the heat shock transcription factor 1 (Hsf-1), labeled hTTR V30M/Hsf mice, were used for the 
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experiments8. Animals were housed in pathogen-free conditions, in a controlled-temperature room, maintained 
under a 12 h light/dark period, with water and food ad libitum. Treated animals were given standard mouse 
chow containing 2% (w/w) curcumin (Sigma-Aldrich, St. Louis, MO, USA) starting at age 14 months for 6 weeks 
(treated, n = 12). Control animals were fed regularly (n = 14). Mice were euthanized at 15.5 months of age with a 
solution containing ketamine and medetomidine. Blood samples were collected from the vena cava, plasma was 
separated by centrifugation and stored at − 20 °C prior to analysis. Mice tissues, in particular the gastrointestinal 
tract (stomach, duodenum and colon) and the dorsal root ganglia (DRG) were immediately excised and frozen 
at − 80 °C or fixed in 10% neutral buffered formalin for western blot or light microscopy analysis, respectively.
Determination of TTR levels in mice plasma. Transthyretin levels in mice plasma were quantified 
by radial immunodiffusion (RID) using the Human Prealbumin Bindarid, Radial Immunodiffusion Kit (The 
Binding Site, Birmingham, UK) following the manufacturer’s instructions.
Thyroxine (T4) binding gel electrophoresis. Five microliters of plasma from control and curcumin 
treated mice were incubated with [125I]T4 (specific radioactivity 1250 μ Ci/μ g; Perkin–Elmer, MA, USA). Plasma 
proteins were separated by native PAGE49. The gel was dried, subjected to phosphor imaging (Typhoon 8600; 
Molecular Diagnostics, Amersham Biosciences) and analyzed using the ImageQuant program version 5.1.
Isoelectric focusing (IEF) in semi-denaturing conditions. Isoelectric focusing (IEF) of plasma TTR 
was performed as detailed elsewhere49. Thirty microliters of plasma from control and curcumin treated mice were 
subjected to native electrophoresis (PAGE). The TTR gel band was excised and applied to a semi-denaturing (4 M 
urea) pH 4–6.5 gradient isoelectric focusing (IEF) gel run for 6 h at 1200 V. Proteins were stained with Coomassie 
Blue. The gels were scanned and subjected to densitometry analysis using the ImageQuant program version 5.1.
Semi-quantitative immunohistochemistry (SQ-IHC) and Congo red staining. Immunohistochemistry 
and histological analyses of mice GI tract and DRG were performed as described previously50. Tissue sections (5 μ m 
thick) were deparaffinated in histoclear and rehydrated in a descent alcohol series. Endogenous peroxidase activity 
was quenched with 3% hydrogen peroxide in methanol and sections were blocked in 10% fetal bovine serum, 1% 
bovine serum albumin and 0.5% Triton X-100 in PBS. The primary antibodies were: rabbit polyclonal anti-TTR 
(1:1000) (DAKO, Denmark), goat polyclonal anti-BiP (1:50), rabbit polyclonal anti-Fas death receptor (1:200), goat 
polyclonal anti-IL-1β (1:25), goat polyclonal anti-TNF-α (1:25), rabbit polyclonal anti-NF-κ B p65 (1:25) (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), rabbit polyclonal anti-cleaved caspase-3 (1:100, R&D Systems, Minneapolis, 
MN) which were diluted in blocking solution and incubated overnight at 4 °C. Antigen visualization was performed 
with the biotin–extravidin peroxidase ABC kit (Vector, Burlingame, CA) using hydrogen peroxide and diaminoben-
zidine as substrate and chromogen, respectively. Semi-quantitative immunohistochemical (SQ-IHC) analysis was 
performed using Image-Pro Plus version 5.1 software. This application enables the measurement of the area occupied 
by pixels corresponding to the immunohistochemistry substrate’s color that is normalized relatively to the total area. 
The area occupied by chromogen represents the total amount of antigen present and all brown staining was auto-
mated quantified by the image analysis software. Each slide was analyzed in five different representative areas at 20x 
magnification.
Tissues were also stained with Congo red and observed under polarized light for the detection of amyloid 
deposits21. Briefly, deparaffinated tissue sections were incubated for 20 min with 0.01% NaOH in 80% ethanol 
saturated with NaCl followed by staining with 0.5% Congo red in the previous solution. Then, preparations were 
washed with tap water, stained with hematoxilin and analyzed under polarized light. Amyloid was identified by 
distinctive apple green birefringence. All image analyses were carried out independently by two investigators 
unaware of the origin of the tested tissue sections.
Total protein extracts and Western blot analysis. Stomach and DRG were homogenized on ice in a 
small glass rod homogenizer with lysis buffer containing 5 mM EDTA, 2 mM EGTA, 20 mM MOPS, 1% Triton 
X-100, 1 mM PMSF and Protease Inhibitor Mix (GE Healthcare). After centrifugation (14,000 rpm for 20 min 
at 4 °C) protein concentration in the supernatant was determined by the Bradford protein assay (Bio-Rad, CA, 
USA). Western blotting was performed as previously described17. Protein lysates were run on 15% SDS-PAGE 
(50 μ g/lane) and transferred to a nitrocellulose Hybond-C membrane using a Mini Trans-Blot Cell (Bio-Rad) 
system. Membranes were incubated overnight at 4 °C with the primary antibodies: rabbit polyclonal anti-TTR 
(1:1000) (DAKO, Denmark), rabbit polyclonal anti-BiP (1:1000) and mouse monoclonal anti- glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) (1:3000) (Abcam, Cambridge, UK). Detection was performed with 
LuminataTM Crescendo (enhanced chemiluminescence, Millipore, Billerica, MA). Quantification of blots was 
performed with a Bio-Rad ChemiDoc XRS system using the IMAGELAB software and immunosignals were 
normalized to GAPDH expression. Results are presented as normalized density ± SEM.
Culture of primary bone-marrow derived macrophages. Bone marrow-derived macrophages 
were obtained from femurs and tibias of 14 months-old hTTR V30M/Hsf mice and were cultured at 4 × 106 
cells per petri dish for 6 days (bacterial plates; Sterilin) in 8 mL of RPMI 1640 (Lonza) supplemented with 10% 
heat-inactivated fetal bovine serum, 1% sodium pyruvate, 1% HEPES, 1% L-glutamine (GIBCO), 0.05 mM 2- 
mercaptoethanol (Sigma-Aldrich) and 20% L929 cell-conditioned media (LCCM), as previously described51. At 
day 6, macrophages were harvested and seeded into 24-well tissue culture plates (Orange Scientific, Braine-l′ 
Alleud, Belgium) at 0.5 × 106 cells/mL. Cells were rested and stimulated at day 7, overnight in the absence (con-
trol) or presence of curcumin (final concentration in the medium 0.01 μ M to 10 μ M). Oligomeric TTR prepared 
as described above was then added to the medium at appropriate dilution (2 μ g/mL). After different incubation 
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periods (2 and 24 h), cells were washed with PBS and fixed with 4% ice-cold paraformaldehyde for subsequent 
confocal microscopy analysis.
Confocal Laser Microscopy. For mouse cell imaging by fluorescence analysis, cells were plated over 
a glass coverslip lipopolysaccharide (LPS) free, in a 24 well plate, and fixed with 4% paraformaldehyde. After 
permeabilization, fixed cells were blocked with phosphate buffer supplemented with 10% fetal bovine serum 
and 0.5% Triton X-100 for 1 h at room temperature and incubated overnight at 4 °C with rabbit polyclonal anti-
body against Early Endosome Antigen 1 (EEA1, 1:250, Sigma-Aldrich) to localize early endosomes, mouse 
anti- Lysosomal-Associated Membrane Protein 1 (LAMP- 1, 1:75, Abcam) as a marker for lysosomes and rat 
monoclonal anti-F4/80 (1:100, Serotec), as a macrophage marker. For detection of primary antibodies, anti-rabbit 
Alexa Fluor 568, anti-rat Alexa Fluor 594 or anti-mouse Alexa Fluor 568 (1:1,000; Molecular Probes, Invitrogen) 
were incubated for 1 h at room temperature. Coverslips were mounted in Vectashield with DAPI (Vector 
Laboratories) and visualized under a Laser Scanning Confocal microscope Leica SP5.
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